We are live on ! Find out more
IBO

Impact BioMedical
IBO

24 hedge funds and large institutions have $726K invested in Impact BioMedical in 2025 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

103% more capital invested

Capital invested by funds: $358K → $726K (+$368K)

14% more funds holding

Funds holding: 21 → 24 (+3)

7.4% more ownership

Funds ownership: 4.42% → 11.82% (+7.4%)

0% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 6

Holders
24
Holders Change
+3
Holders Change %
+14.29%
% of All Funds
0.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
6
Reduced
6
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$377K
2
Millennium Management
Millennium Management
New York
+$72.9K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$15.5K
4
Jane Street
Jane Street
New York
+$7.45K
5
HF
HRT Financial
New York
+$7.16K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$9.48K
2
TSS
Two Sigma Securities
New York
-$3.04K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$2.36K
4
Citigroup
Citigroup
New York
-$1.8K
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$24
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$412K +$377K +711,980 +692%
BlackRock
2
BlackRock
New York
$131K +$3.82K +7,216 +3%
Millennium Management
3
Millennium Management
New York
$69.6K +$72.9K +137,823 New
Geode Capital Management
4
Geode Capital Management
Massachusetts
$37.6K +$15.5K +29,269 +65%
Two Sigma Investments
5
Two Sigma Investments
New York
$20.1K +$4.41K +8,327 +26%
TSS
6
Two Sigma Securities
New York
$11.5K -$3.04K -5,746 -20%
Susquehanna International Group
7
Susquehanna International Group
Pennsylvania
$8.33K -$2.36K -4,461 -21%
Jane Street
8
Jane Street
New York
$7.11K +$7.45K +14,086 New
HF
9
HRT Financial
New York
$6K +$7.16K +13,533 New
State Street
10
State Street
Massachusetts
$5.96K – – –
Northern Trust
11
Northern Trust
Illinois
$5.16K +$5.41K +10,225 New
MAC
12
Mason & Associates (California)
California
$5.05K – – –
Morgan Stanley
13
Morgan Stanley
New York
$4.68K – – –
UBS Group
14
UBS Group
Switzerland
$1.09K -$9.48K -17,919 -89%
TRCT
15
Tower Research Capital (TRC)
New York
$720 -$8 -16 -1%
Bank of America
16
Bank of America
North Carolina
$467 +$400 +756 +450%
Wells Fargo
17
Wells Fargo
California
$113 -$15 -29 -11%
NFSG
18
Newbridge Financial Services Group
Florida
$43 – – –
DB
19
Danske Bank
Denmark
$2 – – –
SRCM
20
Signature Resources Capital Management
California
$2 – – –
Citigroup
21
Citigroup
New York
$1 -$1.8K -3,395 -100%
Group One Trading
22
Group One Trading
Illinois
$1 – – –
Fidelity Investments
23
Fidelity Investments
Massachusetts
– -$24 -36 Closed
Royal Bank of Canada
24
Royal Bank of Canada
Ontario, Canada
– +$16 +31 +3,100%

IBO Hedge Fund Activity: Q4 2025 in Review

24 of the 8,232 institutional investors tracked by Wall St. Rank reported a position in Impact BioMedical (IBO) for Q4 2025, worth a combined $726K — up 103% from $358K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new IBO positions and 1 closed out — a net gain of 3 holders — while 6 added to existing stakes and 6 trimmed.

The largest buyer was Vanguard Group, adding an estimated $377K. The largest seller was UBS Group, cutting an estimated $9.48K.

  • 24 institutional investors held Impact BioMedical (IBO) as of Q4 2025, up from 21 in Q3 2025.
  • Funds reported $726K of Impact BioMedical stock for Q4 2025, up 103% quarter-over-quarter.
  • 4 funds opened new Impact BioMedical positions in Q4 2025 and 1 closed out, a net change of +3 holders.
  • The largest Impact BioMedical buyer in Q4 2025 was Vanguard Group, an estimated $377K added.
  • The largest Impact BioMedical seller in Q4 2025 was UBS Group, an estimated $9.48K sold.

Based on aggregated 13F filings for Q4 2025.